Gerald Chan
Director/Miembro de la Junta en Cognito Therapeutics, Inc. .
Perfil
Gerald Chan is currently a Director at Cognito Therapeutics, Inc. He was previously a Director at Stavvy, Inc.
Cargos activos de Gerald Chan
| Empresas | Cargo | Inicio |
|---|---|---|
Cognito Therapeutics, Inc.
 Cognito Therapeutics, Inc. BiotechnologyHealth Technology Cognito Therapeutics, Inc. is a clinical-stage neurotechnology company based in Cambridge, MA. Cognito Therapeutics is developing disease-modifying therapeutic approaches to treat neurodegenerative disorders using its non-invasive neuromodulation platform. The company's lead therapy is currently in a pivotal study (HOPE) in Alzheimer's disease and has been awarded FDA breakthrough device designation. Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases. The company was founded by Li-Huei Tsai and Ed Boyden, and Brent A. Vaughan has been the CEO of the company since 2020. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Gerald Chan.
| Empresas | Cargo | Fin |
|---|---|---|
Stavvy, Inc.
 Stavvy, Inc. Packaged SoftwareTechnology Services Stavvy, Inc. provides information technology services. The company is headquartered in Newton, MA. | Director/Miembro de la Junta | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Stavvy, Inc.
Stavvy, Inc. Packaged SoftwareTechnology Services Stavvy, Inc. provides information technology services. The company is headquartered in Newton, MA. | Technology Services |
Cognito Therapeutics, Inc.
Cognito Therapeutics, Inc. BiotechnologyHealth Technology Cognito Therapeutics, Inc. is a clinical-stage neurotechnology company based in Cambridge, MA. Cognito Therapeutics is developing disease-modifying therapeutic approaches to treat neurodegenerative disorders using its non-invasive neuromodulation platform. The company's lead therapy is currently in a pivotal study (HOPE) in Alzheimer's disease and has been awarded FDA breakthrough device designation. Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases. The company was founded by Li-Huei Tsai and Ed Boyden, and Brent A. Vaughan has been the CEO of the company since 2020. | Health Technology |
- Bolsa de valores
- Insiders
- Gerald Chan
